Advertisement

Seizures

  • Eswaran WaranEmail author
Living reference work entry

Abstract

Seizures are a common occurrence in patients with a life-limiting illness. The assessment and management of seizures in the palliative patient require the interplay of many factors, including patient and treatment goals, counterbalanced with the need to maintain quality of life. Throughout this chapter, the reader is provided with current evidence regarding definitions, classification, assessment, and management of seizures. Antiepileptic medications are discussed in detail, with an emphasis on the administration routes, commonly used in the palliation population. Current concepts regarding status epilepticus are outlined, including pathophysiology and management. The chapter concludes with a comment on seizures, driving, and the palliative patient.

Keywords

Seizure Epilepsy Antiepileptic Status epilepticus Brain tumor Stroke 

References

  1. Aranda A, Foucart G, Ducasse J, Grolleau S, McGonigal A, Valton L. Generalized convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice. Epilepsia. 2010;51(10):2159–67.CrossRefPubMedGoogle Scholar
  2. Avila E, Graber J. Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep. 2010;10(1):60–7.CrossRefPubMedGoogle Scholar
  3. Bausewein C, Hau P, Borasio G, Voltz R. How do patients with primary brain tumours die? Palliat Med. 2003;17(6):558–9.CrossRefPubMedGoogle Scholar
  4. Berg A, Berkovic S, Brodie M, Buchhalter J, Cross J, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51(4):676–85.CrossRefPubMedGoogle Scholar
  5. Bladin C, Alexandrov A, Bellavance A, Bornstein N, Chambers B, Cote R, et al. Seizures after stroke: a prospective multicentre study. Arch Neurol. 2000;57(11):1617–22.CrossRefPubMedGoogle Scholar
  6. van Breemen M, Wilms E, Vecht C. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421–30.CrossRefPubMedGoogle Scholar
  7. Brigo F, Nardone R, Tezzon F, Trinka E. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. Epilepsy Behav. 2015;49:325–36.CrossRefPubMedGoogle Scholar
  8. Brophy G, Bell R, Claassen J, Alldredge B, Bleck T, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23.CrossRefPubMedGoogle Scholar
  9. Camilo O, Goldstein L. Seizures and epilepsy after ischemic stroke. Stroke. 2004;35(7):1769–75.CrossRefPubMedGoogle Scholar
  10. Cancer Institute NSW. Brain tumours and driving: a guide for clinicians [Internet]. Cited 2016 Oct 15. Available from: https://www.nsa.org.au/documents/item/48.
  11. Chen J, Wasterlain C. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5:246–56.CrossRefPubMedGoogle Scholar
  12. Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology. 2000;55(5):693–7.CrossRefPubMedGoogle Scholar
  13. Cramer J, Mintzer S, Wheless J, Mattson R. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother. 2010;10(6):885–91.CrossRefPubMedGoogle Scholar
  14. DeLorenzo R, Hauser W, Towne A, Boggs J, Pellock J, Penberthy L, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029–35.CrossRefPubMedGoogle Scholar
  15. Dickman A, Schneider J. The syringe driver: continuous subcutaneous infusions in palliative care. 4th ed. Oxford: Oxford University Press; 2016.CrossRefGoogle Scholar
  16. Droney J, Hall E. Status epilepticus in a hospice inpatient setting. J Pain Symptom Manag. 2008;36(1):97–105.CrossRefGoogle Scholar
  17. Fisher R, Acevedo C, Arzimanoglou A, Bogacz A, Cross H, Elger C, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–82.CrossRefPubMedGoogle Scholar
  18. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63.CrossRefPubMedGoogle Scholar
  19. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Grewal J, Grewal H, Forman A. Seizures and epilepsy in cancer: etiologies, evaluation, and management. Curr Oncol Rep. 2008;10(1):63–71.CrossRefPubMedGoogle Scholar
  21. Hirtz D, Ashwal S, Berg A, Bettis D, Camfield C, Camfield P, et al. Practice parameter: evaluating a first nonfebrile seizure in children: report of the quality standards subcommittee of the American Academy of Neurology, The Child Neurology Society, and The American Epilepsy Society. Neurology. 2000;55(5):616–23.CrossRefPubMedGoogle Scholar
  22. Hirtz D, Berg A, Bettis D, Camfield C, Camfield P, Crumrine P, et al. Practice parameter: treatment of the child with a first unprovoked seizure: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2003;60(2):166–75.CrossRefPubMedGoogle Scholar
  23. Hosgood J, Kimbrel J, Protus B, Grauer P. Evaluation of subcutaneous phenobarbital administration in hospice patients. Am J Hosp Palliat Med. 2016;33(3):209–13.CrossRefGoogle Scholar
  24. Jacoby A, Gamble C, Doughty J, Marson A, Chadwick D. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology. 2007;68(15):1188–96.CrossRefPubMedGoogle Scholar
  25. Kalviainen R. Intranasal therapies for acute seizures. Epilepsy Behav. 2015;49:303–6.CrossRefPubMedGoogle Scholar
  26. Koekkoek J, Postma T, Heimans J, Reijneveld J, Taphoorn M. Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study. Support Care Cancer. 2016;24(4):1633–8.CrossRefPubMedGoogle Scholar
  27. Krouwer H, Pallagi J, Graves N. Management of seizures in brain tumor patients at the end of life. J Palliat Med. 2000;3(4):465–75.CrossRefPubMedGoogle Scholar
  28. Krumholz A, Wiebe S, Gronseth G, Shinnar S, Levisohn P, Ting T, et al. Practice parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the quality standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2007;69(21):1996–2007.CrossRefPubMedGoogle Scholar
  29. Krumholz A, Wiebe S, Gronseth G, Gloss D, Sanchez A, Kabir A, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;84(16):1705–13.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Lacerda G, Krummel T, Sabourdy C, Ryvlin P, Hirsch E. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology. 2006;67(12 Suppl 4):s28–33.CrossRefPubMedGoogle Scholar
  31. Leppik I, Patel S. Intramuscular and rectal therapies of acute seizures. Epilepsy Behav. 2015;49:307–12.CrossRefPubMedGoogle Scholar
  32. Lorenzl S, Mayer S, Noachtar S, Borasio G. Nonconvulsive status epilepticus in terminally ill patients-a diagnostic and therapeutic challenge. J Pain Symptom Manag. 2008;36(2):200–5.CrossRefGoogle Scholar
  33. Lorenzl S, Mayer S, Feddersen B, Jox R, Noachtar S, Borasio G. Nonconvulsive status epilepticus in palliative care patients. J Pain Symptom Manag. 2010;40(3):460–5.CrossRefGoogle Scholar
  34. Louie A, Chan E, Hanna M, Bauman G, Fisher B, Palma D, et al. Assessing fitness to drive in brain tumour patients: a grey matter of law, ethics, and medicine. Curr Oncol. 2013;20(2):90–6.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Lowenstein D, Alldredge B. Status epilepticus. New Engl J Med J Med. 1998;338:970–6.CrossRefGoogle Scholar
  36. McDonald K. Brain tumors and driving. J Neuro-Oncol. 2011;104(1):399–400.CrossRefGoogle Scholar
  37. Mula M, Kanner A, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013;54(1):199–203.CrossRefPubMedGoogle Scholar
  38. Murray-Brown F, Stewart A. Remember Keppra: seizure control with subcutaneous levetiracetam infusion. BMJ Support Palliat Care. 2016;6(1):12–3.CrossRefPubMedGoogle Scholar
  39. Nasr Z, Paravattil B, Wilby K. Levetiracetam for seizure prevention in brain tumor patients: a systematic review. J Neuro-Oncol. 2016;129(1):1–13.CrossRefGoogle Scholar
  40. O’Connor N. Personal communication. 2016.Google Scholar
  41. Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W. The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien Klin Wochenschr. 2002;114(21–22):911–6.PubMedGoogle Scholar
  42. Pace A, Villani V, DiLorenzo C, Guariglia L, Maschio M, Pompili A, et al. Epilepsy in the end-of-life phase in patients with high-grade gliomas. J Neuro-Oncol. 2013;111(1):83–6.CrossRefGoogle Scholar
  43. Palliative Care Expert Group. Therapeutic guidelines: palliative care. 3rd ed. Melbourne: Therapeutic Guidelines Limited; 2010.Google Scholar
  44. Patsalos P, Froscher W, Pisani F, van Rijn C. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43(4):365–85.CrossRefPubMedGoogle Scholar
  45. Perucca P, Gilliam F. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792–802.CrossRefPubMedGoogle Scholar
  46. Perucca E, Meador K. Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl. 2005;112(Suppl 181):30–5.CrossRefGoogle Scholar
  47. Pharmaceutical Society of Australia. Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2014.Google Scholar
  48. Remi C, Lorenzl S, Vyhnalek B, Rastorfer K, Feddersen B. Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects. J Pain Palliat Care Pharmacother. 2014;28(4):371–7.CrossRefPubMedGoogle Scholar
  49. Remi C, Zwanzig V, Feddersen B. Subcutaneous use of lacosamide. J Pain Symptom Manag. 2016;51(2):e2–4.CrossRefGoogle Scholar
  50. Ropper A, Samuels M, Klein J. Adam and Victor’s principles of neurology. 10th ed. New York: McGraw-Hill; 2014.Google Scholar
  51. Rosati A, De Masi S, Guerrini R. Antiepileptic drug treatment in children with epilepsy. CNS Drugs. 2015;29(10):847–63.CrossRefPubMedPubMedCentralGoogle Scholar
  52. Rosetti A, Hurwitz S, Logroscino G, Bromfield E. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry. 2006;77(5):611–5.CrossRefGoogle Scholar
  53. Rossetti A, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol. 2010;23(6):603–9.CrossRefPubMedGoogle Scholar
  54. Rossetti A, Jeckelmann S, Navy J, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-Oncology. 2014;16(4):584–8.CrossRefPubMedGoogle Scholar
  55. Schiff D, Lee E, Nayak L, Norden A, Reardon D, Wen P. Medical management of brain tumors and the sequelae of treatment. Neuro-Oncology. 2015;17(4):488–504.CrossRefPubMedGoogle Scholar
  56. Schneider J, Good P, Ravenscroft P. Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion. J Pain Symptom Manag. 2006;31(6):563–7.CrossRefGoogle Scholar
  57. Scholtes F, Renier W, Meinardi H. Non-convulsive status epilepticus: causes, treatment, and outcome in 65 patients. Epilepsia [Internet]. 1994;35(5):1104–12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC486466/ CrossRefGoogle Scholar
  58. Silverman I, Restrepo L, Mathews G. Poststroke seizures. Arch Neurol. 2002;59(2):195–201.CrossRefPubMedGoogle Scholar
  59. Singh G, Rees J, Sander J. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry. 2007;78(4):342–9.CrossRefPubMedPubMedCentralGoogle Scholar
  60. Sizoo E, Koekkoek J, Postma T, Heimans J, Pasman H, Deliens L, et al. Seizures in patients with high-grade glioma: a serious challenge in the end-of-life phase. BMJ Support Palliat Care. 2014;4:77–80.CrossRefPubMedGoogle Scholar
  61. Sofou K, Krisjansdottir R, Papachatzakis N, Ahmadzadeh A, Uvebrant P. Management of prolonged seizures and status epilepticus in childhood: a systematic review. J Child Neurol. 2009;24(8):918–26.CrossRefPubMedGoogle Scholar
  62. Sykes L, Wood E, Kwan J. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev. 2014;(1):CD005398.  https://doi.org/10.1002/14651858.CD005398.pub3.
  63. Thomas S, Mehta M, Kuo J, Robins H, Khuntia D. Current practices of driving restriction implementation for patients with brain tumors. J Neuro-Oncol. 2011;103(3):641–7.CrossRefGoogle Scholar
  64. Tremont-Lukats I, Ratilal B, Armstrong T, Gilbert M. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;16(2):CD004424.Google Scholar
  65. Trinka E, Cock H, Hesdorffer D, Rossetti A, Scheffer I, Shinnar S, et al. A definition and classification of status epilepticus – report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56(10):1515–23.CrossRefPubMedGoogle Scholar
  66. Twycross R, Wilcock A, Howard P, editors. Palliative care formulary. 5th ed. Nottingham: Palliativedrugs.com Ltd; 2014.Google Scholar
  67. Wallace E, O’Reilly M, Twomey M. A review of the use of antiepileptic drugs in high grade central nervous system tumors. Am J Hosp Palliat Med. 2012;29(8):618–21.CrossRefGoogle Scholar
  68. Wells G, Mason L, Foreman E, Chambers J. Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. Age Ageing. 2016;45(2):321–2.CrossRefPubMedGoogle Scholar
  69. Yang C, Dao R, Lee T, Lu C, Huang S, Chung W. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology. 2011;77(23):2025–33.CrossRefPubMedGoogle Scholar
  70. Young B, Jordan K, Doig G. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality. Neurology. 1996;47:83–9.CrossRefPubMedGoogle Scholar

Copyright information

© Crown Copyright 2018

Authors and Affiliations

  1. 1.Royal Darwin HospitalTiwiAustralia
  2. 2.Territory Palliative CareTiwiAustralia

Personalised recommendations